Dialysis-Related Amyloidosis Treatment Act of 2025
- house
- senate
- president
Last progress June 20, 2025 (5 months ago)
Introduced on June 20, 2025 by Brian Babin
Sponsors (3)
House Votes
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Senate Votes
Presidential Signature
AI Summary
This bill would require Medicare to cover and pay for treatments for dialysis-related amyloidosis. It defines these treatments as FDA‑approved items or services given in dialysis facilities, plus any supplies or services needed to deliver the treatment. It also says these treatments are separate from the usual “renal dialysis services” bundle, so they can be paid for on their own. The changes take effect as soon as the law is enacted.
Key points:
- Who is affected: People on Medicare who get dialysis and have dialysis‑related amyloidosis; dialysis facilities that provide their care.
- What changes: Medicare must cover and pay for FDA‑approved treatments for this condition, including necessary related supplies and services; these payments are made separately from the standard dialysis bundle.
- When: Immediately upon enactment.